share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Secora Michael

SEC ·  Aug 16 05:27
Summary by Futu AI
Michael Secora, the Chief Financial Officer of Recursion Pharmaceuticals, completed a series of transactions involving the company's Class A Common Stock. On August 13 and 14, 2024, Secora exercised options to acquire a total of 78,750 shares at a price of $2.22 per share. Concurrently, he sold 30,000 shares through open market transactions, with sale prices ranging from $6.3455 to $6.3501 per share. The total market value of the disposed shares amounted to $190,434. Following these transactions, Secora's direct holdings in Recursion Pharmaceuticals totaled 1,365,343 shares of Class A Common Stock.
Michael Secora, the Chief Financial Officer of Recursion Pharmaceuticals, completed a series of transactions involving the company's Class A Common Stock. On August 13 and 14, 2024, Secora exercised options to acquire a total of 78,750 shares at a price of $2.22 per share. Concurrently, he sold 30,000 shares through open market transactions, with sale prices ranging from $6.3455 to $6.3501 per share. The total market value of the disposed shares amounted to $190,434. Following these transactions, Secora's direct holdings in Recursion Pharmaceuticals totaled 1,365,343 shares of Class A Common Stock.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.